• Chief Healthcare ExecutiveChief Healthcare Executive
  • Formulary WatchFormulary Watch
  • Managed Healthcare Executive
  • Medical EconomicsMedical Economics
Managed Healthcare Executive
Managed Healthcare Executive
Resource Centers
View MoreAsthmaAtrial FibrillationBiosimilarsBlood CancerCovid-19DermatologyDigital HealthEye CareHemophiliaHIVLiver DiseaseMultiple SclerosisPost-Acute CarePrescription Digital TherapeuticsRespiratory ConditionsSleep DisordersSubstance Use DisorderType II InflammationUlcerative ColitisVaccines
Spotlight
AMCP AnnualAsembia’s 2022 Specialty Pharmacy SummitAMCP NexusExamining Evolving Treatment Paradigms in the Hemophilia B Space Payer Provider Perspectives: Prescription Digital Therapeutics: Reimagining Care in Behavior-Driven ConditionsPBMI National ConferenceUnbranded Biologics: An Overview
Business
View MoreBusiness StrategyChronic DiseaseConsumersDrug CostsDrug PipelineFormularyHealth ManagementHealth/Disease StrategyHospitals & ProvidersIndustry AnalysisPharmacyPolitics and PolicyPractice ManagementReimbursementTechnology
News
Media
Expert Interviews
K-Cast
Medical World News
Podcasts
Population Health Perspectives
ConferencesPartners
Publications
MHE Publication
Supplements And Featured Publications
Events
Virtual Events
CME/CE
Resources
PBM Leaders
Sponsored
Sponsored Content
Surveys
Subscribe
eNewsletter
Print Subscription
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Informations

© 2023 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.

Advertisement
Resource CentersSee All >
  • Asthma
  • Atrial Fibrillation
  • Biosimilars
  • Blood Cancer
  • Covid-19
  • Dermatology
  • Digital Health
  • Eye Care
  • Hemophilia
  • HIV
  • Liver Disease
  • Multiple Sclerosis
  • Post-Acute Care
  • Prescription Digital Therapeutics
  • Respiratory Conditions
  • Sleep Disorders
  • Substance Use Disorder
  • Type II Inflammation
  • Ulcerative Colitis
  • Vaccines
Spotlight
  • AMCP Annual
  • Asembia’s 2022 Specialty Pharmacy Summit
  • AMCP Nexus
  • Examining Evolving Treatment Paradigms in the Hemophilia B Space
  • Payer Provider Perspectives: Prescription Digital Therapeutics: Reimagining Care in Behavior-Driven Conditions
  • PBMI National Conference
  • Unbranded Biologics: An Overview
BusinessSee All >
  • Business Strategy
  • Chronic Disease
  • Consumers
  • Drug Costs
  • Drug Pipeline
  • Formulary
  • Health Management
  • Health/Disease Strategy
  • Hospitals & Providers
  • Industry Analysis
  • Pharmacy
  • Politics and Policy
  • Practice Management
  • Reimbursement
  • Technology
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Informations
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.

Type II Inflammation

  1. home
  2. clinical
  3. type-ii-inflammation
 

Patients With Moderate-to-Severe Atopic Dermatitis Experience Impaired QOL, Feel Disease Burden

September 07, 2022

A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis (AD) to understand how they are usually treated with Dupixent in the real world.

Management of EoE May Need to Be Rethought to Reduce Treatment Burden, Impact on Quality of Life

September 02, 2022

Therapeutic goals of reducing eosinophil counts below a certain level in eosinophilic esophagitis (EoE) has a marginal benefit for the impact on quality of life and treatment burden.

Patients Maintain Controlled AD Even After Reduction of Dupixent Dose

August 10, 2022

Patients with persistently controlled atopic dermatitis (AD) who had their doses reduced were able to maintain their low disease activity.

Overlap of Upper Airway Diseases Increases Risk of Outpatient Visit Burden

August 09, 2022

Patients with chronic rhinosinusitis with nasal polyps had the greatest number of outpatient visits and the shortest time between visits.

Coping Strategies Related to Perception of Health-Related Quality of Life in EoE

August 02, 2022

Less-effective coping strategies, such as passive and palliative reaction, were associated with a significant impact on health-related quality of life in eosinophilic esophagitis (EoE).

Patients on Dupixent Experience Temporary Increase in Eosinophil Levels

July 07, 2022

The increases had no impact on the efficacy of the drug and were rarely associated with symptoms or sequelae.

HRQOL Declined in Certain Areas for Patients With AD During the Pandemic

June 24, 2022

Certain problems such as pain/discomfort, worrying and fear of the persistence/recurrence of atopic dermatitis (AD) became more common among patients with AD since the start of the COVID-19 pandemic.

FDA Expands Approval of Dupixent to Children 6 Months and Older With Moderate-to-Severe Atopic Dermatitis

June 10, 2022

Dupixent was already approved for patients 6 years and older. The new approval makes the drug available to children 6 months to 5 years whose atopic dermatitis is inadequately controlled.

Dupixent Safe, Effective Over 52 Weeks in Adolescents With Moderate-to-Severe AD

June 01, 2022

A 52-week open-label extension study supported the long-term use of Dupixent to treat adolescents with moderate-to-severe atopic dermatitis.

Real-World Evidence Corroborates Dupixent Clinical Trials in Atopic Dermatitis

May 25, 2022

Data gathered from electronic medical records found that the results in a real-world patient population with atopic dermatitis were consistent with those found in clinical trials.

Advertisement
Advertisement